Royalty Report: Drugs, Ophthalmological, Therapeutic – Collection: 26094


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 17


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 17

Primary Industries

  • Drugs
  • Ophthalmological
  • Therapeutic
  • Pharmaceuticals
  • Disease
  • Biotechnology
  • Delivery
  • Cancer
  • Diagnostic
  • Medical
  • Device

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26094

License Grant
The Licensor hereby granted to the Licensee a royalty-bearing, exclusive worldwide right and license, with the right to grant sublicenses, for Cytokine Modulator (CM) as a therapeutic drug containing a single active pharmaceutical ingredient or two or more active pharmaceutical ingredients where no component of the CM is tacrolimus, cyclosporine, ISAtx24, Rapamycin (Sirolimus), Pimecrolimus, Everolimus, another calcineurin inhibitor or a corticosteroid. Subject to the terms and conditions of this Agreement, the Licensor shall grant the Licensee a right of reference to the Licensor Generated Data to Exploit Licensed Products in the Licensed Combination Field.
License Property
BOE Disease means the following diseases Wet Age-related Macular Degeneration; Dry Age-related Macular Degeneration; Posterior uveitis (chorioentinitis); Retinitis Pigmentosa; Retinal Vein Occlusion; Retinal detachment; Retinal Artery Occlusion; Proliferative diabetic retinopathy; Post-operative inflammation; Persistant Macular Edema; Neovascular diseases involving the retina or uveal tract such as neovascular glaucoma, neovascularization following a combined vitrectomy and lensectomy, neovascularization of the optic nerve, and neovascularization due to penetration of the eye or contusive ocular injury; Inflammation due to ocular trauma; Open-angle glaucoma; Closed-angle glaucoma; Exudative macular edema; Diabetic Retinopathy; Diabetic Macular Edema; Cystoid macular edema; Chronic posterior uveitis; Allograft rejection; Behcet's syndrome; Chorioiditis; Crystalline retinopathy; Optic neurtitis; Proliferative sickle cell retinopathy; Proliferative vitreoretinopathy; Retinopathy of prematurity; Vitreitis; Temporal arteritis; Fuchs' Dystrophy; Dacryocystitis; Giant cell arteritis; Sympathetic ophthalmia; Pars planitis; Pan Uveitis; and all other similar diseases as agreed to by the Parties.
Field of Use
Licensee has certain proprietary in vitro and in vivo models of ophthalmic diseases, and clinical expertise in developing ophthalmic therapeutics.  Collaboration Combination Field means use of a Collaboration Combination by Local Administration to treat the diseases.

IPSCIO Record ID: 613

License Grant
The Licensor hereby grants to the Licensee, a sole and exclusive irrevocable right and license, including the right to sublicense, under and to Intellectual Property to make, have made, use, sell, offer for sale, import or otherwise commercialize Licensed Products in the Critical Field of Use, and to Jointly-Owned Intellectual Property to make, have made, use, sell, offer for sale, import or otherwise commercialize Topical siRNA and Licensed Products in the Critical Field of Use and the Non-Critical Field of Use. Scope of Collaboration. The Parties shall work together to research and develop the Topical siRNA.
License Property
Licensor is a RNAi delivery technology company and the Licensee has proprietary technology and expertise in the area of ophthalmic pharmaceutical clinical development.
Field of Use
The License and Collaboration agreement is in the field of the treatment of ophthalmic diseases characterized by excessive or unwanted neovasculature, angiogenesis or leakage.

Critical Field of Use means the treatment of ophthalmic diseases characterized by excessive or unwanted neovasculature, angiogenesis or leakage such as but not limited to Wet AMD, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, neovascular glaucoma, retinopathy of prematurity, Von Hippel Angioma, von-hippel landau, Corneal Neovascularization, Rubeosis, Pterygium or Iris Neovascularization as well as, dry AMD, drusen and uveitis.

IPSCIO Record ID: 27999

License Grant
The Agreement with the Licensee is structured so that the Licensor receives consideration based on its adjusted gross profit from its sales of Silicone Oil on a quarterly basis.
License Property
The Licensor operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of ophthalmic medical devices, ophthalmic pharmaceuticals and vascular devices.

Silicone oil is indicated for use as a prolonged retinal tamponade in selected cases of complicated retinal detachments when other interventions are not appropriate for patient management. Complicated retinal detachments or recurrent retinal detachments occur most commonly following perforating injuries or in eyes with proliferative vitreoretinopathy (PVR), proliferative diabetic retinopathy (PDR), cytomegalovirus (CMV) retinitis, or giant tears.
—Silicone oil is also indicated in the treatment of retinal detachments due to acquired immunodeficiency syndrome (AIDS)-related CMV retinitis and other viral infections.

Field of Use
Silicone Oils are insoluble in aqueous fluid and allow maintenance of retinal positioning for extended periods.

IPSCIO Record ID: 234135

License Grant
Prior to entering into the New Collaboration Agreement, the Company held the worldwide license from Licensor for the use of Licensor’s proprietary insert technology for the treatment of all ocular diseases other than uveitis. The New Collaboration Agreement expands the license to include uveitis, including NIPU, in Europe, the Middle East and Africa and allows the Company to also pursue an indication for posterior uveitis for ILUVIEN in those territories.  The New Collaboration Agreement converts the Company’s obligation to share 20% of its net profits to a royalty payable on global net revenues of ILUVIEN.
License Property
ILUVIEN is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).

Uveitis is an inflammatory disease of the uveal tract, which is comprised of the iris, ciliary body and choroid, that can lead to severe vision loss and blindness.

Diabetic Macular Edema (DME) is an accumulation of fluid in the macula—part of the retina that controls our most detailed vision abilities—due to leaking blood vessels. In order to develop DME, you must first have diabetic retinopathy. Diabetic retinopathy is a disease that damages the blood vessels in the retina, resulting in vision impairment.

Field of Use
This agreement pertains to the drug industry relating for the treatment of vision impairment.

IPSCIO Record ID: 311

License Grant
Licensor hereby grants to each Licensee a non-exclusive, worldwide license under the Licensed Patents for the Term of this Agreement to make, have made, use, offer for sale, sell, import, and export Licensed Product in the Field in the Territory.
License Property
“Licensed Product” shall mean the protein aflibercept, whether sold under the trade name Zaltrap or any other name, and any pharmaceutical formulation of the protein aflibercept with one or more excipients, in each case that is intended for use in the Field in the Territory.
ZALTRAP is an FDA-approved anti-cancer medicine given in combination with a chemotherapy regimen called FOLFIRI (foal-feer-ee) to treat colorectal cancer that has spread.

IP relates to the Davis-Smyth patents, and certain other patents, in all indications for human use other than the prevention or treatment of eye diseases and eye disorders through administration to the eye. Under the terms of the ZALTRAP Agreement, payments are required to be made to licensor based on sales of ZALTRAP in the United States and of ZALTRAP that is manufactured in the United States and sold outside the United States through May 7, 2016.

The partner commenced sales of ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion, in combination with 5-fluorouracil, leucovorin, irinotecan ('FOLFIRI'), for patients with metastatic colorectal cancer (“mCRC”) that is resistant to or has progressed following an oxaliplatin-containing regimen, in the United States in the third quarter of 2012 and in certain European and other countries in the first quarter of 2013.

The licensee and partner globally collaborate on the development and commercialization of ZALTRAP.

Licensed Patents
.S. Patent No. 5,952,199
U.S. Patent No. 6,100,071
U.S. Patent No. 6,383,486
U.S. Patent No. 6,897,294
U.S. Patent No. 7,771,721
U.S. Patent No. 8,268,313
U.S. Patent No. 8,268,591
U.S. Patent No. 8,273,353
U.S. Patent Application No. 08/643,839
U.S. Patent No. 7,998,931
U.S. Patent No. 8,007,799
U.S. Patent No. 8,287,873
U.S. Patent Application No. 12/002,605

Field of Use
“Field” shall mean and be limited to the prevention or treatment of any disease or condition in a human through the administration of Licensed Product, excluding only the Ocular Field. As used herein, “Ocular Field” shall mean the prevention or treatment of eye diseases and eye disorders in a human through the administration of Licensed Product to the eye (including, but not limited to, the prevention or treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and/or myopic choroidal neovascularization in a human).

IPSCIO Record ID: 239019

License Grant
The Japanese Licensor grants a sole and exclusive license under the Patent Rights and the Technical Information and Know-How to manufacture or have manufactured the Compound in or outside of the Territory for production of Product to be sold in the Territory, to make the Product and have the Product made by a Third Party or Affiliate as described in this Article, and, to develop, use, promote, market, offer to sell, sell and otherwise commercialize the Product in the Territory.

The Licensee intends to develop, manufacture, use, obtain governmental approval for, offer to sell, sell, and commercialize the Product in certain countries or areas of North America.

License Property
The patents and know-how are for Drugs for ameliorating ocular circulatory disorders;   1 ,4-dihydropyridine derivatives and pharmaceutical composition thereof;   Anti-inflammatory agents and inhibitors against increase in ocular tension caused by irradiation with lasers, containing 1,4- dihydropyridine derivatives; and,  Inhibitor of visual function disturbance caused by optic nerve cell disorder due to factor other than ophthalmic circulatory disorder.

Compound shall mean the substance 3- (4-Allyl-1-piperazinyl)-2, 2-dimethylpropylmethyl 1,4-dihydro-2, 6-dimethyl-4-(3-nitrophenyl)-3, 5-pyridine dicarboxylate dihydrochloride, (also known as iganidipine dihydrochloride and KS-288), including without limitation, all enantiomers and any other alternate or derivative forms.

Product shall mean any ophthalmic pharmaceutical product containing the Compound as an active pharmaceutical ingredient (API), whether alone or in combination with other API s, in any and all delivery forms and presentations other than transdermal, oral, or parenteral dosage forms.

Field of Use
The product is for use in the ophthalmic field.

IPSCIO Record ID: 261

License Grant
Licensor hereby grants to Licensee and Licensee hereby accepts a non-exclusive license under the Licensed Patents for the Term of this Agreement to
(i) make and have made Licensed Product in the Territory solely for use or sale in the Field in the Territory, and to export Licensed Product that is initially made in bulk or other non-finished form in the Territory solely for the purpose of converting such Licensed Product to filled and/or finished form outside the Territory for reimportation into the Territory.
License Property
Licensed Product shall mean aflibercept, which is being sold in the Field in the Territory under the trade name Eyleaâ„¢ (aflibercept) as of the Effective Date, and any pharmaceutical formulation containing aflibercept that is intended for use in the Field in the Territory.

Licensed Patents shall mean (i) U.S. Patent Nos. 5,952,199; 6,100,071; 6,383,486; 6,897,294; and 7,771,721.

Field of Use
Field shall mean and be limited to the prevention or treatment of eye diseases and eye disorders in a human through the administration of Licensed Product to the eye, (including, but not limited to, the prevention or treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and/or myopic choroidal neovascularization in a human).

IPSCIO Record ID: 197910

License Grant
The Licensor announced an amendment of its exclusive license and collaboration agreement with Licensee that grants Licensee rights to Licensor’s Durasertâ„¢ three-year treatment for posterior segment uveitis (Durasert) in Europe, the Middle East and Africa (EMEA).  With this license, Licensee plans to pursue a secondary indication for ILUVIEN for posterior segment uveitis in EMEA, which could accelerate the uveitis indication approval as well as commercialization. Licensor retains commercialization rights for posterior segment uveitis in all other countries, including the United States. The amended agreement also modifies the companies’ existing global licensing agreement for ILUVIEN for the treatment of diabetic macular edema (DME).
License Property
ILUVIEN is for the treatment of posterior segment uveitis.   ILUVIEN®, a micro-insert for diabetic macular edema.

Posterior segment uveitis is a chronic, non-infectious inflammatory disease affecting the posterior segment of the eye, often involving the retina, which is believed to be a leading cause of blindness in the developed and developing countries. It affects people of all ages, producing swelling and destroying eye tissues, which can lead to severe vision loss and blindness. In the U.S. and EU, posterior uveitis affects approximately 200,000 people, annually. Today, patients with posterior uveitis are typically treated with systemic steroids, but over time frequently develop serious side effects that can limit effective dosing. Patients then often progress to steroid-sparing therapy with systemic immune suppressants or biologics, which themselves can have severe side effects including an increased risk of cancer.

Field of Use
This agreement pertains to the drug industry relating to products for treating eye diseases.

IPSCIO Record ID: 344589

License Grant
Licensor grants an exclusive, worldwide license and sublicense, with the right to sublicense, under the Licensor Technology, based on existing agreements in place, to research, develop, use, have used, make, have made, import or have imported, export or have exported, offer for sale or have offered for sale, and/or sell or have sold Licensed Products in the Field.
License Property
The various patents relate to Treating Ocular Disorders and include but are not limited to
Susceptibility Genes for Age Related Maculopathy (ARM) on Chromosome 10q26;
Variants in Complement Regulatory Genes Predict Age-Related Macular Degeneration;
Methods for Diagnosing, Preventing or Treating Drusen Formation;
Diagnostics and Therapeutics for Aortic Aneurysm;
Diagnostics and Therapeutics for Ocular disorders;
Diagnostics and Therapeutics for Drusen Associated Ocular Disorders;
Diagnostics and therapeutics for macular degeneration-related disorders;
Factor H-Based Diagnostics;
Methods and Compositions for Treating Ocular Disorders;
Methods and Reagents for Treatment and Diagnosis of Vascular Disorders and Age-Related Macular Degeneration;
Association of SNPs with Complement Related Diseases;
Genetic Variants Increase the Risk of Age-Related Macular Degeneration;
Diagnosis and Therapeutic Target for Macular Degeneration;
Methods and Compositions for Prognosing, Detecting, and Treating Age-Related Macular Degeneration;
Method Evolved · for Recognition and Testing of Age Related Macular Degeneration (Mert-Armd);
Method of Detecting Ocular Diseases and Pathologic Conditions and Treatment of Same; and,
Genes Associated with Macular Degeneration.
Field of Use
Licensee has the rights to develop and commercialize diagnostic tests to predict genetic predisposition to late stage age-related macular degeneration (AMD).

AMD is an insidious progressive eye disorder that starts with relatively harmless tiny yellow deposits on the retina (the light sensitive tissue in the eye) and increases in prevalence and severity with age. The end stage of this condition, called neovascular or 'wet AMD', develops in 10 to 20% of all cases, causes profound loss of central vision and is the leading source of legal blindness in people over age 50 in the developed world. It is caused by abnormal growth of fragile and leaky blood vessels (choroidal neovascularization or 'CNV') in the macula (a small area where vision is keenest at the center of the retina) in response to chronic inflammatory stress.

Field shall mean any and all diagnostic, which includes prognostic, uses for research, laboratory developed tests or in vitro diagnostic tests markets, for use with any and all types of technology platforms.

IPSCIO Record ID: 1039

License Grant
A federal jury found the Company liable for certain inventions relating to the use of verteporfin (the active pharmaceutical ingredient in Visudyne®) as the photoactive agent in the treatment of certain eye diseases including AMD –  a treatment for the wet form of Age related macular degeneration.

IPSCIO Record ID: 4190

License Grant
The Israeli Licensor has agreed to grant the Licensee an exclusive worldwide License for its therapeutic drug in the field of ophthalmic diseases in return for which we have agreed to grant shares and warrants representing approximately 90% of the issued share capitalization of our company.  

The Licensee will be granted to an Israeli subsidiary of the Licensor which will be transferred in whole to us at closing.

License Property
The drug, CF101 (known generically as IB-MECA), is being developed to treat three ophthalmic indications dry eye syndrome; glaucoma and uveitis.
Field of Use
Concurrently with the closing the Licensee is required to enter into a service Agreement with the Licensor or its affiliate for the management of all activities relating to the pre-clinical and clinical studies to be performed for the development of the drug.

IPSCIO Record ID: 29275

License Grant
The Company, who develops miniaturized, injectable, drug delivery systems and the Licensee, amended and restated their February 2005 License and collaboration agreement relating to Iluvien, the company’s Phase III investigative treatment for diabetic macular edema, and certain other products.
License Property
Diabetic macular edema is swelling of the retina in diabetes mellitus due to leaking of fluid from blood vessels within the macula.

The macula is the central portion of the retina, a small area rich in cones, the specialized nerve endings that detect color and upon which daytime vision depends.

Field of Use
Collaboration Field shall mean the treatment and prevention of eye diseases in humans; provided, however, that the treatment and prevention of [*] is excluded from the Collaboration Field.

IPSCIO Record ID: 28715

License Grant
Pursuant to an acquisition agreement, the Party entered into a License Agreement, in which Can-Fite granted the Licensee a sole and exclusive worldwide License for the use of CF101.
License Property
CF101 (known generically as IB-MECA), is being developed to treat three ophthalmic indications dry eye syndrome; glaucoma and uveitis. We are currently (i) conducting a Phase III trial with respect to the development of CF101 for dry eye syndrome, under an Investigational New Drug, or IND, application with the United States Food and Drug Administration, or FDA; (ii) conducting a Phase II trial with respect to the development of CF101 for the treatment of glaucoma; and (iii) preparing for Phase II study of the development of CF101 for uveitis.
CF101 is a highly-selective, orally bioavailable small molecule synthetic drug, which targets the A3 adenosine receptor (A3AR). We believe that CF101 has a favorable safety profile and a potent anti-inflammatory activity, mediated via its capability to inhibit the production of inflammatory cytokines, such as TNF-a, MMPs, IL-1, and IL-6. This is mediated by activation of the A3AR, which is highly expressed in inflammatory tissues in contrast to normal tissues where expression levels of the receptor are very low. We believe that the anti-inflammatory and neuroprotective effects of CF101 make it an attractive candidate for use in the treatment of a variety of ophthalmic diseases.
Field of Use
The field of ophthalmic diseases.

IPSCIO Record ID: 7490

License Grant
The Japanese Licensee will acquire rights to the Licensor's lead candidate, ACU-4429, and potential backup compounds in Japan and certain other Asian countries and will collaborate with the Licensor on the further development and commercialization of Collaboration Products in the Shared territory.
License Property
ACU-4429 is the Licensor's small-molecule visual cycle modulator (VCM) being developed to treat dry age-related macular degeneration (dry AMD), which occurs when light-sensitive cells in the macula slowly break down, gradually blurring central vision in the affected eye.
Field of Use
Field means the diagnosis, treatment, palliation and/or prevention of ophthalmologic conditions, maladies and diseases, including age-related macular degeneration and diabetic retinopathy.

IPSCIO Record ID: 3199

License Grant
The Licensor entered into a License and collaboration Agreement with Licensee for the global development and commercialization outside the United States of EYLEA® (aflibercept) Injection.

Pursuant to the Amendment, the Licensor consented to the commercialization of EYLEA in Japan pursuant to a Co-Promotion and Distribution Agreement, which was executed concurrently with the execution of the Amendment.

License Property
Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, oncology, rheumatoid arthritis, allergic asthma, and atopic dermatitis.

EYLEA® (aflibercept) Injection is indicated for the treatment of patients with neovascular (Wet) Age-related Macular Degeneration (AMD).

IPSCIO Record ID: 5405

License Grant
In a related party transaction, we have entered into a license agreement with this development-stage biotechnology company to use our delivery technology in connection with their proposed neutraceutical product with potential application for macular degeneration and retinitus pigmentosa, a disease affecting the retina.
Field of Use
The rights granted apply to the medical industry.

IPSCIO Record ID: 3092

License Grant
The Licensor granted the Licensee an exclusive worldwide License to develop and commercialize diagnostic and pharmaceutical products based on compounds that inhibit the Licensor's proprietary target gene RTP801 through RNA interference.
License Property
The lead product candidate under the Agreement is the Company's drug candidate PF-655 (called in the past RTP801i-14) for treating ophthalmic diseases and potentially non-ophthalmic diseases, is currently in Phase II clinical trials for wet AMD and DME.

In March 2011, the Licensor amended its License Agreement with the Licensee.  Under the amendment, the Licensor will conduct at its own expense a Phase IIb trial of PF-655 in diabetic macular edema, under a protocol mutually agreed by both Parties.  Under the amendment, the Licensor will deliver the trial data to the Licensee upon completion.  After its review of the data, the Licensee will either make a milestone payment to the Licensor in an amount which exceeds the anticipated cost of the trial and resume responsibility for continued development of PF-655 at the Licensee's expense, or will terminate its license and return to the Licensor the rights to the product. In further consideration of the Licensor's conducting the Phase IIb trial, the Licensee agreed to increase the overall development and product approval milestone payments associated with the first ophthalmic use of PF-655 and to increase the royalty rates under the agreement. The Licensor may terminate the Phase IIb clinical trial if an independent monitoring committee determines futility at interim review points set forth in the protocol.

Field of Use
PF-655 is for the treatment of wet Age-related Macular Degeneration (wet AMD)2 (hereinafter “wet AMD”) and Diabetic Macular Edema (DME)3 (hereinafter “DME”).
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.